Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Gregory Cote, Kyriakos Papadopoulos, Amita Patnaik, Drew Rascoe, Lon Smith, Andrea Bullock, Keith Flaherty, Geoffrey Shapiro, Jordan Berlin, Manish Monga, Thomas Habermann, Thomas Witzig, Chester Lin, Lin-Feng Tsai, Agnes Elekes, Naoto Ohi, Kunihiko Tatsu |
Title | Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer |
Journal | Molecular Cancer Therapeutics |
Vol | |
Issue | |
Date | |
URL | http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short |
Abstract Text | Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OPB-111077 | STAT3 Inhibitor 21 | OPB-111077 is an inhibitor of STAT3, which may result in antitumor activity (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118, PMID: 29898591, PMID: 29511132). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | diffuse large B-cell lymphoma | not applicable | OPB-111077 | Phase I | Actionable | In a Phase I trial, a patient with diffuse large B-cell lymphoma demonstrated a partial response when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). | detail... |
Unknown unknown | olfactory neuroblastoma | not applicable | OPB-111077 | Phase I | Actionable | In a Phase I trial, a patient with esthesioneuroblastoma demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). | detail... |
Unknown unknown | cholangiocarcinoma | not applicable | OPB-111077 | Phase I | Actionable | In a Phase I trial, a patient with cholangiocarcinoma demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). | detail... |
Unknown unknown | prostate cancer | not applicable | OPB-111077 | Phase I | Actionable | In a Phase I trial, a patient with prostate cancer demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). | detail... |
Unknown unknown | kidney cancer | not applicable | OPB-111077 | Phase I | Actionable | In a Phase I trial, a patient with kidney cancer demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). | detail... |
Unknown unknown | stomach cancer | not applicable | OPB-111077 | Phase I | Actionable | In a Phase I trial, two gastric cancer patients demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118). | detail... |